Dr. Reddy's Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on May 09, 2025.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's Laboratories announced audited consolidated financial results for Q4 and FY25 (year ended March 31, 2025). Q4 FY25 revenue grew 20% YoY to Rs. 85,060 million, while FY25 revenue rose 17% YoY to Rs. 325,535 million, largely aided by the acquired Haleon Nicotine Replacement Therapy (NRT) business. Q4 profit before tax surged 25% YoY to Rs. 20,054 million; FY25 PBT grew 7% to Rs. 76,784 million. Profit attributable to equity holders rose 22% YoY in Q4 (Rs. 15,939 million) but only 2% for the full year (Rs. 56,544 million). EBITDA margin stood at 29.1% in Q4 and 28.3% for FY25. The Board recommended a final dividend of Rs. 8 per equity share and approved the re-appointment of Mr. G V Prasad as Co-Chairman & MD for 5 years from January 30, 2026. Statutory auditors issued an unqualified opinion on the financial statements. Ongoing US FCPA investigations (since 2020) remain pending with uncertain outcomes.
Strong Q4 topline growth driven by the Haleon NRT acquisition and core generics business should support the stock, though full-year PAT growth was muted at just 2% YoY. The final dividend of Rs. 8 per share offers steady income to shareholders, and leadership continuity with Mr. Prasad's re-appointment provides stability. Investors should note the unresolved FCPA investigation as a lingering risk.